Trader Nektar Therapeutics - NKTR CFD
Ajouter aux favoris- Résumé
- Données historiques
- Événements
- Compte de résultat
- Bilan
- Flux de trésorerie
- Capital
Conditions de trading
| Écart | 0.0174 | ||||||||
|
Frais de position longue en overnight
Long position overnight fee
Aller vers la plateforme | -0.025457% | ||||||||
|
Frais de position courte en overnight
Short position overnight fee
Aller vers la plateforme | 0.003235% | ||||||||
| Durée des frais en overnight | 21:00 (UTC) | ||||||||
| Quantité minimale négociée | 1 | ||||||||
| Devise | USD | ||||||||
| Marge | 20% | ||||||||
| Bourse | United States of America | ||||||||
| Commission sur la négociation | 0% |
*Information provided by Capital.com
Nektar Therapeutics ESG Risk Ratings
High Medium Low Negligible
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Chiffres clés
| Fermeture précédente* | 0.5868 |
| Ouvert* | 0.6099 |
| Variation sur 1 an* | -82.62% |
| Fourchette du jour* | 0.5993 - 0.6154 |
| Fourchette sur 52 semaines | 0.58-5.18 |
| Volume moyen (10 jours) | 3.36M |
| Volume moyen (3 mois) | 103.73M |
| Capitalisation boursière | 117.19M |
| Ratio C/B | -100.00K |
| Actions en circulation | 189.24M |
| Revenu | 88.83M |
| EPS | -2.21 |
| Dividende (rendement en %) | N/A |
| Bêta | 1.10 |
| Prochaine date de publication des résultats | Aug 2, 2023 |
Toutes les données sont fournies par Refinitiv, à l'exception des données marquées d'un astérisque, qui sont des *données fournies par Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Clôture | Change | Change (%) | Ouverture | High | Low |
|---|---|---|---|---|---|---|
| Jun 2, 2023 | 0.6043 | 0.0148 | 2.51% | 0.5895 | 0.6155 | 0.5895 |
| Jun 1, 2023 | 0.5868 | -0.0172 | -2.85% | 0.6040 | 0.6174 | 0.5815 |
| May 31, 2023 | 0.5995 | -0.0223 | -3.59% | 0.6218 | 0.6249 | 0.5995 |
| May 30, 2023 | 0.6147 | -0.0169 | -2.68% | 0.6316 | 0.6399 | 0.5895 |
| May 26, 2023 | 0.6262 | -0.0032 | -0.51% | 0.6294 | 0.6448 | 0.6094 |
| May 25, 2023 | 0.6227 | -0.0305 | -4.67% | 0.6532 | 0.6576 | 0.6194 |
| May 24, 2023 | 0.6494 | -0.0295 | -4.35% | 0.6789 | 0.6815 | 0.6294 |
| May 23, 2023 | 0.6694 | -0.0300 | -4.29% | 0.6994 | 0.7247 | 0.6694 |
| May 22, 2023 | 0.7145 | -0.0044 | -0.61% | 0.7189 | 0.7517 | 0.6994 |
| May 19, 2023 | 0.7153 | 0.0308 | 4.50% | 0.6845 | 0.7400 | 0.6594 |
| May 18, 2023 | 0.6501 | -0.0565 | -8.00% | 0.7066 | 0.7101 | 0.6431 |
| May 17, 2023 | 0.7800 | 0.0000 | 0.00% | 0.7800 | 0.7800 | 0.7800 |
| May 5, 2023 | 0.7800 | 0.0000 | 0.00% | 0.7800 | 0.7800 | 0.7800 |
| May 4, 2023 | 0.7500 | 0.0000 | 0.00% | 0.7500 | 0.7500 | 0.7500 |
| May 3, 2023 | 0.7600 | 0.0000 | 0.00% | 0.7600 | 0.7600 | 0.7600 |
| Apr 25, 2023 | 0.8200 | 0.0500 | 6.49% | 0.7700 | 0.8200 | 0.7700 |
| Apr 24, 2023 | 0.7600 | -0.0500 | -6.17% | 0.8100 | 0.8100 | 0.7600 |
| Apr 21, 2023 | 0.8200 | 0.0000 | 0.00% | 0.8200 | 0.8300 | 0.8000 |
| Apr 20, 2023 | 0.8100 | -0.0700 | -7.95% | 0.8800 | 0.8800 | 0.8100 |
| Apr 19, 2023 | 0.8800 | 0.0200 | 2.33% | 0.8600 | 0.9100 | 0.8500 |
Nektar Therapeutics Events
| Heure (UTC) (UTC) | Pays | Événement |
|---|---|---|
| Thursday, June 8, 2023 | ||
| Heure (UTC) (UTC) 21:00 | Pays US
| Événement Nektar Therapeutics Annual Shareholders Meeting Nektar Therapeutics Annual Shareholders MeetingForecast -Previous - |
| Heure (UTC) (UTC) 21:00 | Pays US
| Événement Nektar Therapeutics Annual Shareholders Meeting Nektar Therapeutics Annual Shareholders MeetingForecast -Previous - |
| Wednesday, August 2, 2023 | ||
| Heure (UTC) (UTC) 20:00 | Pays US
| Événement Q2 2023 Nektar Therapeutics Earnings Release Q2 2023 Nektar Therapeutics Earnings ReleaseForecast -Previous - |
| Wednesday, November 1, 2023 | ||
| Heure (UTC) (UTC) 10:59 | Pays US
| Événement Q3 2023 Nektar Therapeutics Earnings Release Q3 2023 Nektar Therapeutics Earnings ReleaseForecast -Previous - |
- Annuel
- Trimestriel
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Revenu total | 92.055 | 101.907 | 152.915 | 114.617 | 1193.32 |
| Revenu | 92.055 | 101.907 | 152.915 | 114.617 | 1193.32 |
| Coût des recettes, total | 21.635 | 24.897 | 19.477 | 21.374 | 24.412 |
| Résultat brut | 70.42 | 77.01 | 133.438 | 93.243 | 1168.91 |
| Total des frais d'exploitation | 468.221 | 548.01 | 578.026 | 554.652 | 505.391 |
| Total des frais de vente/Généraux/Admin | 92.333 | 122.844 | 104.682 | 98.712 | 81.443 |
| Recherche et développement | 218.323 | 400.269 | 408.678 | 434.566 | 399.536 |
| Charges (revenus) inhabituelles | 135.93 | 0 | 45.2 | 0 | 0 |
| Produits d'exploitation | -376.166 | -446.103 | -425.111 | -440.035 | 687.932 |
| Produits (charges) d'intérêts, nets Hors exploitation | 11.183 | -52.767 | -18.836 | -0.019 | -5.207 |
| Résultat net avant impôts | -364.983 | -523.28 | -443.947 | -440.054 | 682.725 |
| Résultat net après impôts | -368.198 | -523.837 | -444.44 | -440.644 | 681.358 |
| Résultat net avant éléments extra | -368.198 | -523.837 | -444.44 | -440.644 | 681.358 |
| Résultat net | -368.198 | -523.837 | -444.44 | -440.667 | 681.313 |
| Revenu disponible pour les actionnaires ordinaires, hors éléments exceptionnels | -368.198 | -523.837 | -444.44 | -440.644 | 681.358 |
| Bénéfice disponible pour les actionnaires ordinaires, y compris les éléments exceptionnels | -368.198 | -523.837 | -444.44 | -440.667 | 681.313 |
| Résultat net dilué | -368.198 | -523.837 | -444.44 | -440.667 | 681.313 |
| Moyenne pondérée des actions diluées | 187.138 | 183.298 | 178.581 | 174.993 | 180.119 |
| BPA dilué hors éléments extraordinaires | -1.96752 | -2.85784 | -2.48873 | -2.51807 | 3.78282 |
| BPA dilué normalisé | -1.49539 | -2.85784 | -2.32421 | -2.51807 | 3.78282 |
| Total des éléments extraordinaires | -0.023 | -0.045 | |||
| Other Operating Expenses, Total | -0.011 | ||||
| Autres, nets | 0 | -24.41 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Revenu total | 21.594 | 22.023 | 23.625 | 21.585 | 24.822 |
| Revenu | 21.594 | 22.023 | 23.625 | 21.585 | 24.822 |
| Coût des recettes, total | 7.06 | 6.233 | 4.972 | 5.115 | 5.315 |
| Résultat brut | 14.534 | 15.79 | 18.653 | 16.47 | 19.507 |
| Total des frais d'exploitation | 156.304 | 74.492 | 77.926 | 174.421 | 141.382 |
| Total des frais de vente/Généraux/Admin | 21.081 | 21.939 | 22.534 | 20.521 | 27.339 |
| Recherche et développement | 30.469 | 34.74 | 33.59 | 42.74 | 107.253 |
| Charges (revenus) inhabituelles | 97.694 | 11.58 | 16.83 | 106.045 | 1.475 |
| Produits d'exploitation | -134.71 | -52.469 | -54.301 | -152.836 | -116.56 |
| Produits (charges) d'intérêts, nets Hors exploitation | -2.371 | -4.075 | -4.903 | -6.132 | 26.293 |
| Résultat net avant impôts | -137.081 | -56.544 | -59.204 | -158.968 | -90.267 |
| Résultat net après impôts | -137.018 | -59.688 | -59.049 | -159.068 | -90.393 |
| Résultat net avant éléments extra | -137.018 | -59.688 | -59.049 | -159.068 | -90.393 |
| Résultat net | -137.018 | -59.688 | -59.049 | -159.068 | -90.393 |
| Revenu disponible pour les actionnaires ordinaires, hors éléments exceptionnels | -137.018 | -59.688 | -59.049 | -159.068 | -90.393 |
| Bénéfice disponible pour les actionnaires ordinaires, y compris les éléments exceptionnels | -137.018 | -59.688 | -59.049 | -159.068 | -90.393 |
| Résultat net dilué | -137.018 | -59.688 | -59.049 | -159.068 | -90.393 |
| Moyenne pondérée des actions diluées | 188.875 | 188.251 | 187.641 | 186.8 | 185.848 |
| BPA dilué hors éléments extraordinaires | -0.72544 | -0.31707 | -0.31469 | -0.85154 | -0.48638 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| BPA dilué normalisé | -0.38924 | -0.27708 | -0.25639 | -0.48254 | -0.48122 |
| Autres, nets |
- Annuel
- Trimestriel
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total de l'actif à court terme | 545.968 | 795.581 | 1138.01 | 1421.55 | 1437.69 |
| Espèces et placements à court terme | 504.977 | 733.955 | 1061.9 | 1324.86 | 1335.35 |
| Trésorerie et équivalents | 88.227 | 25.218 | 198.955 | 96.363 | 194.905 |
| Investissements à court terme | 416.75 | 708.737 | 862.941 | 1228.5 | 1140.44 |
| Total des créances, nettes | 5.981 | 22.492 | 38.889 | 36.802 | 43.213 |
| Accounts Receivable - Trade, Net | 5.981 | 22.492 | 38.889 | 36.802 | 43.213 |
| Total Inventory | 19.202 | 15.801 | 15.292 | 12.665 | 11.381 |
| Other Current Assets, Total | 15.808 | 23.333 | 18.02 | 15.387 | 21.293 |
| Total Assets | 710.6 | 1117.19 | 1538.77 | 1977.36 | 2150.17 |
| Property/Plant/Equipment, Total - Net | 85.886 | 177.535 | 186.138 | 199.176 | 48.851 |
| Property/Plant/Equipment, Total - Gross | 210.617 | 325.574 | 324.626 | 327.051 | 169.358 |
| Accumulated Depreciation, Total | -124.731 | -148.039 | -138.488 | -127.875 | -120.507 |
| Goodwill, Net | 76.501 | 76.501 | 76.501 | 76.501 | 76.501 |
| Long Term Investments | 0 | 64.828 | 136.662 | 279.119 | 582.889 |
| Other Long Term Assets, Total | 2.245 | 2.744 | 1.461 | 1.01 | 4.244 |
| Total Current Liabilities | 68.204 | 85.2 | 115.779 | 353.893 | 82.002 |
| Accounts Payable | 12.98 | 9.747 | 22.139 | 19.234 | 5.854 |
| Accrued Expenses | 55.224 | 75.453 | 93.549 | 79.525 | 61.763 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 0.091 | 6.441 | 14.385 | ||
| Total Liabilities | 343.962 | 437.681 | 461.472 | 571.965 | 432.597 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 246.95 |
| Long Term Debt | 0 | 246.95 | |||
| Other Liabilities, Total | 275.758 | 352.481 | 345.693 | 218.072 | 103.645 |
| Total Equity | 366.638 | 679.508 | 1077.3 | 1405.39 | 1717.57 |
| Common Stock | 0.019 | 0.019 | 0.018 | 0.017 | 0.017 |
| Additional Paid-In Capital | 3574.72 | 3516.64 | 3388.73 | 3271.1 | 3147.93 |
| Retained Earnings (Accumulated Deficit) | -3201.19 | -2833 | -2309.16 | -1864.72 | -1424.05 |
| Other Equity, Total | -6.907 | -4.157 | -2.295 | -1.005 | -6.316 |
| Total Liabilities & Shareholders’ Equity | 710.6 | 1117.19 | 1538.77 | 1977.36 | 2150.17 |
| Total Common Shares Outstanding | 188.56 | 185.468 | 180.091 | 176.505 | 173.53 |
| Prepaid Expenses | 3.908 | 31.834 | 26.45 | ||
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0 | 248.693 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Total de l'actif à court terme | 491.066 | 545.968 | 599.483 | 665.536 | 733.455 |
| Espèces et placements à court terme | 456.827 | 504.977 | 546.387 | 619.316 | 667.025 |
| Trésorerie et équivalents | 76.955 | 88.227 | 105.758 | 77.545 | 67.993 |
| Investissements à court terme | 379.872 | 416.75 | 440.629 | 541.771 | 599.032 |
| Total des créances, nettes | 2.995 | 5.981 | 11.532 | 10.006 | 30.22 |
| Accounts Receivable - Trade, Net | 2.995 | 5.981 | 11.532 | 10.006 | 30.22 |
| Total Inventory | 20.235 | 19.202 | 19.057 | 16.969 | 15.379 |
| Other Current Assets, Total | 11.009 | 15.808 | 22.507 | 19.245 | 20.831 |
| Total Assets | 561.743 | 710.6 | 781.006 | 861.987 | 1024.12 |
| Property/Plant/Equipment, Total - Net | 69.271 | 85.886 | 102.699 | 108.788 | 175.276 |
| Goodwill, Net | 0 | 76.501 | 76.501 | 76.501 | 76.501 |
| Long Term Investments | 0 | 0 | 8.928 | 37.363 | |
| Other Long Term Assets, Total | 1.406 | 2.245 | 2.323 | 2.234 | 1.521 |
| Total Current Liabilities | 59.879 | 68.204 | 83.989 | 104.985 | 105.281 |
| Accounts Payable | 3.696 | 12.98 | 5.329 | 12.346 | 12.617 |
| Accrued Expenses | 56.183 | 55.224 | 78.66 | 92.639 | 92.664 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 320.878 | 343.962 | 368.783 | 403.255 | 416.227 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 260.999 | 275.758 | 284.794 | 298.27 | 310.946 |
| Total Equity | 240.865 | 366.638 | 412.223 | 458.732 | 607.889 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 0.019 | 0.019 | 0.019 | 0.019 | 0.019 |
| Additional Paid-In Capital | 3584.74 | 3574.72 | 3561.88 | 3549.36 | 3537.79 |
| Retained Earnings (Accumulated Deficit) | -3338.21 | -3201.19 | -3141.5 | -3082.46 | -2923.39 |
| Other Equity, Total | -5.681 | -6.907 | -8.169 | -8.191 | -6.532 |
| Total Liabilities & Shareholders’ Equity | 561.743 | 710.6 | 781.006 | 861.987 | 1024.12 |
| Total Common Shares Outstanding | 189.235 | 188.56 | 187.954 | 187.405 | 186.274 |
| Property/Plant/Equipment, Total - Gross | 179.924 | 210.617 | 237.763 | 252.092 | |
| Accumulated Depreciation, Total | -110.653 | -124.731 | -135.064 | -143.304 |
- Annuel
- Trimestriel
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Revenu net/Ligne de départ | -368.198 | -523.837 | -444.44 | -440.667 | 681.313 |
| Liquidités provenant des activités d'exploitation | -304.007 | -412.66 | -313.287 | -328.681 | 718.214 |
| Liquidités provenant des activités d'exploitation | 13.03 | 14.146 | 14.182 | 13.156 | 10.87 |
| Éléments non monétaires | 47.961 | 120.107 | 100.259 | 77.142 | 65.037 |
| Cash Taxes Paid | 0.272 | 0.325 | 0.539 | 0.555 | 0.618 |
| Intérêts payés en espèces | 0 | 0 | 9.742 | 19.199 | 19.471 |
| Variation du fonds de roulement | 0.492 | -23.076 | 16.712 | 21.688 | -39.006 |
| Flux de trésorerie liés aux activités d'investissement | 365.835 | 202.777 | 496.213 | 206.886 | -1379.94 |
| Dépenses d'investissement | -5.676 | -14.989 | -7.258 | -26.285 | -14.239 |
| Autres éléments de flux de trésorerie d'investissement, total | 371.511 | 217.766 | 503.471 | 233.171 | -1365.7 |
| Flux de trésorerie provenant des activités de financement | 1.508 | 36.238 | -80.354 | 23.355 | 851.966 |
| Éléments de flux de trésorerie de financement | 0.75 | 3 | 146.25 | ||
| Émission (remboursement) d'actions, nette | 0.758 | 33.238 | 23.396 | 23.355 | 851.966 |
| Émission (remboursement) de la dette, nette | 0 | 0 | -250 | 0 | 0 |
| Effets de change | -0.327 | -0.092 | 0.02 | -0.102 | -0.101 |
| Variation nette de la trésorerie | 63.009 | -173.737 | 102.592 | -98.542 | 190.143 |
| Deferred Taxes | 2.708 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -137.018 | -368.198 | -308.51 | -249.461 | -90.393 |
| Cash From Operating Activities | -51.915 | -304.007 | -246.304 | -163.417 | -88.424 |
| Cash From Operating Activities | 2.302 | 13.03 | 9.848 | 7.171 | 3.73 |
| Non-Cash Items | 86.135 | 47.961 | 43.798 | 42.541 | -16.271 |
| Cash Interest Paid | 0 | ||||
| Changes in Working Capital | -1.522 | 0.492 | 8.56 | 36.332 | 14.51 |
| Cash From Investing Activities | 40.598 | 365.835 | 325.821 | 214.426 | 130.278 |
| Capital Expenditures | -0.433 | -5.676 | -5.164 | -4.983 | -4.203 |
| Other Investing Cash Flow Items, Total | 41.031 | 371.511 | 330.985 | 219.409 | 134.481 |
| Cash From Financing Activities | 0 | 1.508 | 1.405 | 1.405 | 0.938 |
| Financing Cash Flow Items | 0 | 0.75 | 0.75 | 0.75 | 0.75 |
| Issuance (Retirement) of Stock, Net | 0 | 0.758 | 0.655 | 0.655 | 0.188 |
| Foreign Exchange Effects | 0.045 | -0.327 | -0.382 | -0.087 | -0.017 |
| Net Change in Cash | -11.272 | 63.009 | 80.54 | 52.327 | 42.775 |
| Issuance (Retirement) of Debt, Net | 0 | ||||
| Deferred Taxes | -1.812 | 2.708 |
| Nom de l'investisseur | Catégorie de l'investisseur | Pourcentage de l'encours | Actions détenues | Changement d'actions | Date d'avoirs | Taux du chiffre d'affaires |
|---|---|---|---|---|---|---|
| Invesco Advisers, Inc. | Investment Advisor | 18.9597 | 35878329 | -4631 | 2023-03-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 16.3612 | 30961118 | -250353 | 2023-03-31 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 10.3992 | 19679031 | -3357338 | 2023-03-31 | LOW |
| Deep Track Capital LP | Hedge Fund | 6.501 | 12302237 | 10558989 | 2023-04-04 | HIGH |
| PRIMECAP Management Company | Investment Advisor | 6.0681 | 11483026 | -4176027 | 2023-03-31 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 3.6891 | 6981089 | -354498 | 2023-03-31 | LOW |
| Two Sigma Investments, LP | Hedge Fund | 2.4154 | 4570792 | 3621705 | 2023-03-31 | HIGH |
| Pictet Asset Management Ltd. | Investment Advisor/Hedge Fund | 1.9662 | 3720679 | 2564806 | 2023-03-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.8591 | 3518076 | 74365 | 2023-03-31 | LOW |
| D. E. Shaw & Co., L.P. | Hedge Fund | 1.7447 | 3301661 | 2173745 | 2023-03-31 | LOW |
| BlackRock Financial Management, Inc. | Investment Advisor/Hedge Fund | 1.5904 | 3009612 | -83610 | 2023-03-31 | LOW |
| Renaissance Technologies LLC | Hedge Fund | 1.5873 | 3003696 | 2886585 | 2023-03-31 | HIGH |
| Citadel Advisors LLC | Hedge Fund | 1.513 | 2863070 | 980692 | 2023-03-31 | HIGH |
| AQR Capital Management, LLC | Investment Advisor/Hedge Fund | 1.4469 | 2738029 | 2295171 | 2023-03-31 | MED |
| Jacobs Levy Equity Management, Inc. | Investment Advisor/Hedge Fund | 1.445 | 2734500 | 47031 | 2023-03-31 | MED |
| Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 1.1015 | 2084461 | -465588 | 2023-03-31 | LOW |
| Federated Hermes MDTA LLC | Investment Advisor/Hedge Fund | 1.0045 | 1900784 | 47888 | 2023-03-31 | MED |
| Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 0.8967 | 1696851 | 101227 | 2022-12-31 | LOW |
| Morgan Stanley & Co. LLC | Research Firm | 0.8451 | 1599158 | 579164 | 2023-03-31 | MED |
| Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.8285 | 1567787 | -57116 | 2023-03-31 | LOW |
Pourquoi choisir capital.com? Nos chiffres parlent d'eux-mêmes.
Capital.com Group535K+
Tradeurs
87K+
Clients actifs par mois
$113M+
Volume d'investissement par mois
$64M+
Retrait par mois
Trading calculator
Calculez votre P&L hypothétique si vous aviez ouvert une transaction CFD à une certaine date (sélectionnez une date) et l'aviez fermée à une autre date (sélectionnez une date).
Trade commission
0
- 1:1
Effet de levier
1:1
- 20
- 100
- 500
- 1000
- 10000
Investment
Trade size (Leverage x Investement):
Ouverture
Clôture
Short Long
Nektar Company profile
À propos de Nektar Therapeutics
Nektar Therapeutics, constituée le 3 juin 1998, est une société biopharmaceutique qui découvre et développe des médicaments dans des domaines où les besoins médicaux ne sont pas satisfaits. Le pipeline de recherche et développement de nouveaux médicaments expérimentaux de la Société comprend des traitements contre le cancer et les maladies auto-immunes. La Société exploite sa plateforme de chimie pour découvrir et concevoir de nouveaux candidats médicaments. Ces médicaments candidats utilisent ses plates-formes technologiques de conjugués polymères, conçues pour permettre le développement de nouvelles entités moléculaires ciblant des mécanismes d'action connus. Ses programmes comprennent l'immuno-oncologie (I-O), l'immunologie et l'oncologie-ONZEALD. La Société développe des médicaments conçus pour moduler directement ou indirectement l'activité de cellules immunitaires clés, telles que les cellules lymphocytes T cytotoxiques et les cellules lymphocytes NK (NK), afin d'augmenter leur nombre et d'améliorer leur fonction de reconnaissance et d'attaque des cellules cancéreuses.
- IndustrieBiotechnology / Medical Research
- Adresse455 Mission Bay Blvd S, SAN FRANCISCO, CA, United States (USA)
- Employés740
- CEOHoward Robin
| Industry: | Pharmaceuticals (NEC) |
455 Mission Bay Blvd S
SAN FRANCISCO
CALIFORNIA 94158
US
Compte de résultat
- Annual
- Quarterly
Les gens regardent aussi
Êtes-vous toujours à la recherche d'un broker de confiance?
Rejoignez les plus de 535 000 traders du monde entier qui ont choisi de trader avec Capital.com